← Back to patent-cliff list
Defibrotide sodium
Tier C — Watch / tradeDefibrotide sodium
Gentium Srl
Originator
2013
First approval
-
Expiry (public)
$0.22B ▲
Peak sales
Nucleic acid drug
Type
Targets：vWF, PAI-1, TM
Brand：Defitelio, Prociclide, Noravid
Indications (approved)：Hepatic veno-occlusive disease
Regional status
US
Approved
2016-03-30
EU
Approved
2013-10-18
China
-
Japan
Approved
2019-06-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Defibrotide sodium?
Approved indications include: Hepatic veno-occlusive disease.
When does the Defibrotide sodium patent expire?
No public expiry year is available for Defibrotide sodium yet; this page updates once verified.
How do I get a quote for Defibrotide sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29